drugset
drugset / Trial / NCT05183360

A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated

NCT05183360 ↗

Phase 1 Terminated 48 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Part I: The main objectives of this trial are to investigate safety, tolerability, and pharmacokinetics (PK) of BI 706321 in healthy Japanese male subjects following oral administration of multiple rising doses. Part II: The main objectives of this trial are to investigate safety, tolerability, and pharmacokinetics (PK) of BI 706321 in healthy Chinese male subjects following oral administration of single dose.

Timeline

Start
2022-02-07
Primary completion
2022-08-12
Completion
2024-08-08

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 706321 Unknown 2 mg Oral
Subject BI 706321 Unknown 5 mg Oral
Subject BI 706321 Unknown 8 mg Oral
Subject BI 706321 Unknown 10 mg Oral

Indications

No indication recorded.